Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

The 2009 AMSA National Leadership Development Seminar, Australia
The AMSA National Leadership Development Seminar will be held from the 7th to the 9th of September 2009.
generic viagra online
Continued International Investment, Decreased Discrimination Key To Fight Against HIV/AIDS, Says U.N. Secretary-General
U.N. Secretary-General Ban Ki-Moon during a General Assembly meeting Tuesday urged governments not to cut aid for the international fight against HIV/AIDS, the AP/Washington Post reports. Even as Ban "called for "bold action" not only to increase funding but also to break down social barriers to achieve the goal set by world leaders in 2006 of universal access to comprehensive HIV prevention services, treatment, care and support by 2010," he and other speakers at the meeting "reviewing progress and challenges in the battle against AIDS indicated that it will be exceedingly difficult - if not impossible - to reach the goal" (Lederer, AP/Washington Post, 6/16).
News of the day
Caltech Scientists Predict Greater Longevity For Planets With Life
Roughly a billion years from now, the ever-increasing radiation from the sun will have heated Earth into inhabitability; the carbon dioxide in the atmosphere that serves as food for plant life will disappear, pulled out by the weathering of rocks; the oceans will evaporate; and all living things will disappear.
Health Insurance

Amarillo Biosciences Reaches Enrollment Goal In Australian Influenza Phase 2 Clinical Trial

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) announced that it has reached full enrollment in a Phase 2 clinical study of the company"s oral interferon product at the University of Western Australia located in Perth. A total of 200 healthy volunteers meeting all eligibility criteria have been enrolled to 16 weeks of treatment with oral interferon or matching placebo. The double-blind clinical trial being conducted by Dr. Manfred Beilharz and colleagues is expected to show that lozenges containing a low dose of interferon-alpha can prevent infection or reduce the severity of infection with influenza and other common respiratory viruses when taken once a day during a typical winter cold/flu season. Final study results are expected to be available before the end of the year. Amarillo Biosciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009